Corona vaccine Novavax very effective, also against variants

The corona vaccine from the American biotech company Novavax shows an effectiveness of 90.4 percent. The company announced this in a press release on Monday. Novavax verified efficacy for both the original coronavirus and the variants currently circulating in the United States and Mexico. The company is aiming for the third quarter to apply for formal marketing authorization.

–

Novavax comes with the news as a Phase 3 trial of the corona vaccine NVX-CoV2373 in 29,960 subjects in the United States and Mexico has been completed. The effectiveness against the coronavirus was looked at in general, but the effectiveness against certain variants (mainly the British or Alpha variant) was also measured, as well as the effectiveness in risk groups.

This shows an overall effectiveness of 90.4 percent and 100 percent against a serious infection. 63 infections were recorded in the placebo group compared to 14 in the group that received the vaccine. Since the data was collected between January 25 and April 30, at a time when the m became dominant and other variants were also circulating, Novavax also points to the high effectiveness against these corona variants. The vaccine achieves an efficacy of 93.2 percent in these variants. In the group of high-risk patients (over 65s and people with underlying conditions), the effectiveness was 91 percent.

The results also show that the vaccine is generally well tolerated. The most common complaints were pain at the injection site, fatigue, headache and muscle aches.

Novavax’s vaccine is currently the subject of a rolling review at the European Medicines Agency EMA. Belgium has not yet ordered doses of the corona vaccine.

THIS IS THAT. How do adenovaccines like those from Johnson & Johnson and AstraZeneca work?

THIS IS THAT. Your vaccination against corona goes through these steps in a vaccination center

THIS IS THAT. How does an mRNA vaccine work? And how does it differ from a traditional version?

– .